Marcelo A Queiroz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7205862/publications.pdf

Version: 2024-02-01

567281 552781 28 921 15 26 citations h-index g-index papers 30 30 30 1217 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging, 2020, 20, 23.	2.8	145
2	PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison. European Radiology, 2015, 25, 2222-2230.	4. 5	105
3	PET/MR in Cancers of the Head and Neck. Seminars in Nuclear Medicine, 2015, 45, 248-265.	4.6	69
4	PET/MRI and PET/CT in follow-up of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1066-75.	6.4	68
5	Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. Radiographics, 2019, 39, 186-212.	3.3	68
6	Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics, 2020, 40, 1715-1740.	3.3	65
7	Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2212-2221.	6.4	63
8	18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT. Nuclear Medicine Communications, 2015, 36, 1165-1173.	1.1	43
9	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC Cancer, 2015, 15, 1002.	2.6	42
10	Clinical evaluation of a block sequential regularized expectation maximization reconstruction algorithm in 18F-FDG PET/CT studies. Nuclear Medicine Communications, 2017, 38, 57-66.	1.1	42
11	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. PLoS ONE, 2015, 10, e0128842.	2,5	30
12	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics, 2021, 41, 120-143.	3.3	27
13	Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 186-195.	6.4	20
14	Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 892-899.	1.5	19
15	Regorafenib in Patients with Antiangiogenicâ€NaÃ⁻ve and Chemotherapyâ€Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. Oncologist, 2019, 24, 1180-1187.	3.7	19
16	Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. Radiographics, 2020, 40, 1412-1430.	3.3	17
17	Clinical image quality perception and its relation to NECR measurements in PET. EJNMMI Physics, 2014, 1, 103.	2.7	15
18	Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. European Urology Oncology, 2023, 6, 41-48.	5 . 4	14

#	Article	IF	Citations
19	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. Swiss Medical Weekly, 2015, 145, w14116.	1.6	11
20	Aberrant Hypermetabolism of Benign Uterine Leiomyoma on 18F-FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, e413-e414.	1.3	10
21	Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e417-e419.	1.3	8
22	PET/MRI Characterization of Mucinous Versus Nonmucinous Components of Rectal Adenocarcinoma: A Comparison of Tumor Metabolism and Cellularity. American Journal of Roentgenology, 2021, 216, 376-383.	2.2	7
23	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	6.4	6
24	Positron emission tomography/magnetic resonance imaging (PET/MRI): An update and initial experience at HC-FMUSP. Revista Da Associa§ão Médica Brasileira, 2018, 64, 71-84.	0.7	5
25	Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease. Molecular Imaging and Biology, 2022, 24, 453-463.	2.6	2
26	Prostate Cancer Imaging: What We Already Know and What Is on the Horizon. Radiographics, 2022, 42, E123-E124.	3.3	1
27	Hybrid PET/MR: Updated Clinical Use and Potential Applications. Current Radiology Reports, 2016, 4, 1.	1.4	O
28	Neuro: Head and Neck Oncology. , 2018, , 223-248.		O